Antipodean Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOCK
LifeLock, Inc.
LOCK
|
+$22.5M |
| 2 |
Meta Platforms (Facebook)
META
|
+$17.5M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$13.3M |
| 4 |
Amazon
AMZN
|
+$10.3M |
| 5 |
GoDaddy
GDDY
|
+$7.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Silver Trust
SLV
|
+$15.2M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$7.18M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$6.96M |
| 4 |
Coca-Cola Europacific Partners
CCEP
|
+$5.96M |
| 5 |
GoPro
GPRO
|
+$4.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.34% |
| 2 | Consumer Discretionary | 15.86% |
| 3 | Communication Services | 15.12% |
| 4 | Healthcare | 13.97% |
| 5 | Consumer Staples | 7.45% |
Similar funds
Antipodean Advisors's Q3 2016 Portfolio in Review
As of Q3 2016, Antipodean Advisors held 25 positions worth $202M, up 22% from $165M the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Antipodean Advisors deployed $28.1M of net new capital in Q3 2016, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Meta Platforms (Facebook): 141,000 shares worth $18.1M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Medicines Co, an estimated $6.96M trimmed.
- Antipodean Advisors's largest Q3 2016 buy was Meta Platforms (Facebook): 141,000 shares worth $18.1M.
- Antipodean Advisors added most to LifeLock, Inc. in Q3 2016, an estimated $22.5M increase.
- Antipodean Advisors's biggest Q3 2016 reduction was Medicines Co, cutting an estimated $6.96M.
- Antipodean Advisors fully exited iShares Silver Trust in Q3 2016, selling an estimated $15.2M.
- Antipodean Advisors's ten largest holdings make up 85% of its $202M portfolio in Q3 2016.
- Antipodean Advisors opened 5 new positions and closed 9 in Q3 2016.
- Antipodean Advisors's portfolio value rose 22% quarter-over-quarter to $202M.
Based on Antipodean Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.